People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from ...

Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.

MEDVi offers GLP-1 weight loss drugs online, but is it worth it? Review pricing, pros, cons, and what customers have to say.

A patient displays an injection of the weight-loss drug Mounjaro on November 13, 2024. (Sebastián Hidalgo/For The Washington ...

Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 ...

A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart ...

While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three ...

Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

In a clinical trial, the new weight-loss medication retatrutide led to "clinically meaningful weight reduction," with the ...

Retatrutide, Eli Lilly's new experimental drug, helped some participants lose up to 28 percent of their body weight in ...

Retatrutide helped people lose 70 pounds on average, or 28% of their body weight, in a clinical trial. The Eli Lilly weight-loss drug mimics three gut hormones.